Teva's Growth Signal: Biosimilar Launch Targets Eye-Care Market Dominance

TEL AVIV, Israel – June 04, 2026 – Teva Pharmaceutical Industries Ltd. has fired a strategic shot across the bow of the lucrative European ophthalmology market, launching its biosimilar AHZANTIVE® in a direct challenge to Regeneron’s blockbuster eye drug, Eylea®. The rollout, which began in May across Germany, Spain, France, and The Netherlands, is more than just a new product release; it's a critical signal of momentum for Teva’s ambitious 'Pivot to Growth' strategy and a potential turning point for patient access and healthcare budgets across the continent.

AHZANTIVE® (aflibercept) is a biosimilar, a highly similar and equally effective version of the biologic drug Eylea®, used to treat serious, vision-threatening retinal diseases like neovascular ('wet') age-related macular degeneration (nAMD) and diabetic macular edema (DME). For Teva, this launch represents a major push into the high-value ophthalmology space, leveraging its global scale to compete in a market long dominated by a handful of established players.

The 'Pivot to Growth' in Focus

This move is a textbook execution of the 'Pivot to Growth' strategy championed by CEO Richard Francis since its unveiling in May 2023. The strategy is designed to transform the 120-year-old company, long known as a generics giant, into an innovative biopharmaceutical leader. The launch of AHZANTIVE® directly supports several pillars of this plan, primarily by expanding its biosimilar portfolio to offset pricing pressures in the traditional generics market and by focusing business drivers on high-growth areas.

The signal of strength here is not just strategic but financial. After years of navigating significant debt, Teva's turnaround is gaining traction. The company has posted 11 consecutive quarters of growth and saw its net debt-to-EBITDA ratio fall below 3x in late 2025, with a target of 2.0x by 2027. This progress was recently validated when Fitch Ratings upgraded Teva to Investment Grade in May 2026, a clear indicator that the market is buying into its strategic realignment. The AHZANTIVE® launch is poised to fuel this momentum, providing a new revenue stream in a multi-billion-dollar market.

A Crowded Field: Navigating the Aflibercept Biosimilar Wave

Teva is not entering an empty arena. The European market for aflibercept biosimilars is rapidly becoming a crowded and competitive space. The expiry of key patents on Eylea® has triggered a wave of launches, enabled by a series of settlement agreements with originator Regeneron. Teva’s AHZANTIVE® will be competing for market share against several other approved biosimilars.

Sandoz launched its version, Afqlir®, in late 2025, while Celltrion’s Eydenzelt® and Samsung Bioepis's OPUVIZ™ have also entered the fray. With approvals also granted to Biocon, Amgen, and Alvotech, the competitive pressure is immense. This environment will likely lead to aggressive pricing strategies, as companies vie for inclusion in national health system tenders. Teva's success will depend on its ability to leverage its vast European commercial footprint and established relationships with healthcare providers and payers to secure a significant share of the market.

This competitive dynamic is a bellwether for the evolution of the broader biologics market. As more blockbuster drugs lose exclusivity, the biosimilar segment is set to explode, creating both opportunities for companies like Teva and significant challenges for the originators who have long relied on these high-margin products.

A New Vision for Affordability and Access

Beyond corporate strategy and market share battles, the arrival of AHZANTIVE® and its competitors carries profound implications for patients and healthcare systems. Chronic retinal diseases are a leading cause of vision loss and place a heavy burden on patients, their families, and national health budgets, largely due to the high cost and frequency of anti-VEGF injections like Eylea®.

Biosimilars promise to bend this cost curve. A 2025 report from the IQVIA Institute for Human Data Science projected that aflibercept biosimilars could generate cumulative list-price savings of around €747 million across five major European markets by 2031. These savings can be redirected to treat more patients or fund other healthcare innovations, contributing to the long-term sustainability of the system.

“Biosimilars play a critical role in sustainable healthcare systems,” said Yolanda Tibbe, Global Head of Biosimilars at Teva, in the company's announcement. “With this launch, we are expanding our biosimilars portfolio with an important treatment option for people living with serious conditions that can threaten sight.”

However, adoption is not guaranteed. The ophthalmology community has historically been more conservative in its uptake of biosimilars compared to other fields like oncology or rheumatology. Overcoming this inertia will require a concerted effort to build clinician confidence through education and real-world evidence, ensuring that the promise of cost savings translates into tangible benefits for patients.

The Power of Partnership and Pipeline

Teva’s launch is also a masterclass in strategic partnership, a common model for navigating the complex biosimilar landscape. AHZANTIVE® was developed by the German biosimilar specialist Formycon AG, with global commercialization rights held by Klinge Biopharma GmbH. Teva is leveraging its powerful commercial engine through a semi-exclusive agreement with these partners to bring the product to market across most of Europe.

This model allows each company to play to its strengths: Formycon on development, Klinge on licensing, and Teva on market access and sales. This is not their first collaboration; the partners previously worked together on a ranibizumab biosimilar, creating established pathways and synergies that should benefit the AHZANTIVE® launch.

This launch is just one piece of Teva’s broader biosimilar ambition. The company recently secured FDA approval for its Prolia® biosimilar (PONLIMSI™) and has a candidate for Xolair® under review by both the FDA and EMA. With 11 biosimilars already on the market and 13 more in the pipeline, Teva is building a formidable portfolio that serves as a powerful growth engine, demonstrating a clear and sustained commitment to becoming a dominant force in this critical sector of the pharmaceutical industry.